Pharmacotherapy relapse prevention in body dysmorphic disorder.

Trial Profile

Pharmacotherapy relapse prevention in body dysmorphic disorder.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Apr 2016

At a glance

  • Drugs Escitalopram (Primary)
  • Indications Somatoform disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Apr 2016 Primary endpoint of relapse of body dysmorphic disorder (BDD) symptoms (as Measured by the BDD-YBOCS) has been met, according to results published in the American Journal of Psychiatry.
    • 08 Apr 2016 Results published in the American Journal of Psychiatry
    • 01 Mar 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top